Acurx Pharmaceuticals Files Proxy Statement
Ticker: ACXP · Form: DEFA14A · Filed: Aug 5, 2025 · CIK: 1736243
Sentiment: neutral
Topics: proxy-statement, regulatory-filing
TL;DR
Acurx Pharma filed its proxy statement, basically a shareholder meeting notice. No big news here.
AI Summary
Acurx Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEFA14A) on August 5, 2025. This filing is related to the company's proxy materials, which are used to solicit votes from shareholders for an upcoming meeting. The filing does not appear to contain specific proposals or financial details beyond its classification as a proxy statement.
Why It Matters
This filing is a standard regulatory requirement for public companies to communicate with shareholders regarding voting matters, but it doesn't provide new operational or financial information.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not contain new material information that would typically impact stock price or indicate significant risk.
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant
- 0001104659-25-073997 (filing_id) — Accession Number
- 20250805 (date) — Filing Date
FAQ
What type of filing is this DEFA14A for Acurx Pharmaceuticals, Inc.?
This is a Definitive Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934.
When was this DEFA14A filing made by Acurx Pharmaceuticals, Inc.?
The filing was made on August 5, 2025.
What is the Central Index Key (CIK) for Acurx Pharmaceuticals, Inc.?
The CIK for Acurx Pharmaceuticals, Inc. is 0001736243.
What is the Standard Industrial Classification (SIC) code for Acurx Pharmaceuticals, Inc.?
The SIC code for Acurx Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Does this filing indicate any specific proposals or actions to be voted on by shareholders?
The provided text of the filing does not detail specific proposals or actions for shareholder vote; it is a general proxy statement notification.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on August 5, 2025 regarding Acurx Pharmaceuticals, Inc. (ACXP).